CAN LATE GADOLINIUM ENHANCEMENT IN PULMONARY HYPERTENSION PREDICT ADVERSE CLINICAL EVENTS? A CMR SINGLE CENTER STUDY
Siva Soma(Allegheny General Hospital), Robert W Biederman(Allegheny Health Network), Vikas Rathi(Bon Secours Heart & Vascular Institute), George Sokos(Allegheny General Hospital), Raymond L. Benza(Triangle), Vishal Goyal(Chandigarh University), Mark Doyle(Allegheny General Hospital), Diane A Vido(Allegheny General Hospital), Srinivas Murali(Allegheny General Hospital)
Cited by 0
Related Papers
Predicting Survival in Pulmonary Arterial Hypertension
|Circulation|2010|1.5k
Clinical risk factors for portopulmonary hypertension†
|Hepatology|2008|286
Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease
|American Journal of Respiratory and Critical Care Medicine|2009|232
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
|The Lancet Respiratory Medicine|2018|212